Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23129914 | 0.88 | PARP1 (0.36) | PARP1MTNR1AMTNR1BLMNA | |
| SCHEMBL17347389 | 0.88 | PARP1 (0.36) | PARP1MTNR1AMTNR1BLMNA | |
| SCHEMBL17337357 | 0.87 | PARP1 (0.37) | PARP1MTNR1AMTNR1BLMNA | |
| SCHEMBL17337290 | 0.87 | PARP1 (0.37) | PARP1MTNR1AMTNR1BLMNA | |
| SCHEMBL12944900 | 0.86 | PARP1 (0.34) | PARP1MTNR1AMTNR1B | |
| SCHEMBL15861664 | 0.85 | PARP1 (0.36) | PARP1MTNR1AMTNR1BLMNA | |
| SCHEMBL15861663 | 0.85 | PARP1 (0.36) | PARP1MTNR1AMTNR1BLMNA | |
| SCHEMBL20570354 | 0.84 | NPC1 (0.35) | PARP1MTNR1AMTNR1BNPC1RAB9A | |
| SCHEMBL20570349 | 0.84 | NPC1 (0.35) | PARP1MTNR1AMTNR1BNPC1RAB9A | |
| SCHEMBL18827396 | 0.84 | PARP1 (0.36) | PARP1NPC1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9642869-B2 | Boronic acid derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20140194385-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. | 2014-07-10 | — | — | US | disclosed |
| WO-2010130708-A9 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010130708-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194385-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BPGM, GCG, GBA1 | PARP1 1847/4885MTNR1A 938/4885MTNR1B 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.